CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 1983; 33:258-263
doi: 10.3322/canjclin.33.5.258
© 1983 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, R. B.
Right arrow Articles by Mass, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, R. B.
Right arrow Articles by Mass, T.

CA: A Cancer Journal for Clinicians, Vol 33, 258-263, Copyright © 1983 by American Cancer Society

Safe Handling of Chemotherapeutic Agents: A Report from The Mount Sinai Medical Center

Roy B. Jones Ph.D., M.D.1, Robert Frank R.Ph.2, and Terry Mass R.N., B.S.N.3

1 Assistant Professor of Neoplastic Diseases at The Mount Sinai Medical Center in New York, New York.
2 Oncology Pharmacist at The Mount Sinai Medical Center in New York, New York.
3 Oncology Nurse Coordinator at The Mount Sinai Medical Center in New York, New York.

There are no definitive data about the carcinogenic or fetotoxic risk of handling or admixing antineoplastic agents. These agents differ widely in their toxic potential. Although an increase in urinary mutagens may follow exposure, the ultimate meaning of these data is unclear. There are no direct data that these mutagens are either chemotherapeutic agents or their metabolites. Substantial improvements in presently available analytical methodology may be required to detect the trace levels of any involved drugs. Epidemiologic studies aimed at detecting increased numbers of cancers or fetotoxicities among health care personnel who handle antineoplastic agents are desirable, but are not available. In the interim, we feel it is prudent to afford the affected health care personnel the same level of protection required for laboratory workers exposed to substances of similar or identical biohazard potential.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by American Cancer Society.